Literature DB >> 19822056

The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis.

A Boonen1, W Mau.   

Abstract

During the last decade the economic burden of rheumatic diseases has been increasingly recognised. Even though more studies have been published on rheumatoid arthritis (RA) than ankylosing spondylitis (AS) sufficient data is available for comparison of some economic consequences. This overview addresses mainly the societal impact of RA and AS on (1) labour force participation, on (2) the costs of healthcare consumption and reduced productivity and on (3) health in terms of QALY.In order to examine labour force participation comparison with the general population is preferable. These studies demonstrate increased withdrawal from work in both diseases but more frequently in RA. Risk factors for reduced labour force participation in RA and AS are longer disease duration, lower education and unfavourable labour market conditions. The influence of the sex on employment depends on several factors such as the type of disease and the labour force participation of the general population.In RA overall mean direct costs of healthcare consumption and indirect costs of reduced productivity are above that of AS, particularly after long disease duration. Out-of-pocket expenditures costs were higher in females RA patients than in males while this was less clear in AS. The main cost driver in both diseases for all type of costs was reduced physical function.The societal valuation of health (utility) showed similar reductions of quality adjusted life years (QALYs) in RA and AS when compared with the general population.In conclusion, while the societal valuation of the impact of both diseases on health is similar, the decrease in worker participation is more pronounced in RA and direct as well as productivity costs are higher. However, since AS starts at an earlier age, the lifetime economic burden might be higher. There is a strong relation between physical function and each aspect of economic impact.

Entities:  

Mesh:

Year:  2009        PMID: 19822056

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

Review 1.  The balance of tissue repair and remodeling in chronic arthritis.

Authors:  Rik Lories
Journal:  Nat Rev Rheumatol       Date:  2011-10-18       Impact factor: 20.543

2.  An evaluation of a biopsychosocial framework for health-related quality of life and disability in rheumatoid arthritis.

Authors:  Perry M Nicassio; Morgan A Kay; Mara K Custodio; Michael R Irwin; Richard Olmstead; Michael H Weisman
Journal:  J Psychosom Res       Date:  2011-05-14       Impact factor: 3.006

3.  Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.

Authors:  Katrine Løppenthin; Bente Appel Esbensen; Mikkel Østergaard; Rikke Ibsen; Jakob Kjellberg; Poul Jennum
Journal:  Clin Rheumatol       Date:  2016-10-25       Impact factor: 2.980

4.  Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study.

Authors:  Joshua A Wood; Dai-Jung Chung; Shin Ae Park; Allison L Zwingenberger; Christopher M Reilly; Irene Ly; Naomi J Walker; William Vernau; Kei Hayashi; Erik R Wisner; Matthew S Cannon; Philip H Kass; Simon R Cherry; Dori L Borjesson; Paul Russell; Christopher J Murphy
Journal:  J Ocul Pharmacol Ther       Date:  2011-12-16       Impact factor: 2.671

5.  Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study.

Authors:  Louis Bessette; Gerald Lebovic; Brad Millson; Katia Charland; Krishna Donepudi; Tania Gaetano; Valencia Remple; Martin G Latour; Sandra Gazel; Marie-Claude Laliberté; Carter Thorne
Journal:  Rheumatol Ther       Date:  2018-04-09

6.  The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.

Authors:  Ashok Jha; Alex Upton; William C N Dunlop; Ron Akehurst
Journal:  Adv Ther       Date:  2015-09-05       Impact factor: 3.845

7.  Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70.

Authors:  Michelle E Orme; Katherine S Macgilchrist; Stephen Mitchell; Dean Spurden; Alex Bird
Journal:  Biologics       Date:  2012-12-17

8.  Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.

Authors:  An Tran-Duy; Annelies Boonen; Mart A F J van de Laar; Johan L Severens
Journal:  Cost Eff Resour Alloc       Date:  2015-10-07

9.  Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea.

Authors:  Tae-Jin Lee; Bo-Hyun Park; Joon Wan Kim; Kichul Shin; Eun Bong Lee; Yeong-Wook Song
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

10.  Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.

Authors:  A Kavanaugh; D Gladman; D van der Heijde; O Purcaru; P Mease
Journal:  Ann Rheum Dis       Date:  2014-06-18       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.